Xtalks Community Connection Newsletter - August 2026
The August edition of our community newsletter is live, bringing you expert insights on patient-centric care, oncology breakthroughs and innovative approaches in women's health. Be sure to explore our latest content to learn:
Plus, don't miss our community updates: dive into this month's featured life science job openings in manufacturing and business development, cast your vote on the biggest barrier to adopting New Approach Methodologies (NAMs), check out last month's poll results on essential future skills for industry professionals and explore our lineup of upcoming webinars spanning clinical trials, regulatory compliance and biopharma manufacturing.
Check out our upcoming and on-demand webinars (see all) on essential life science industry topics, including:
How Do Online Health Communities Play a Role in Shaping the Patient Experience?
Kristen Hartman, SVP of Strategy & Account Management at Inspire, explores how online patient communities are shaping healthcare decision-making, AI validation and long-term engagement across the treatment lifecycle. Drawing on recent data regarding digital health adoption and growing patient privacy concerns, Hartman highlights how leveraging authentic patient connections transforms health outcomes and elevates patient support beyond the clinic... (read more)
Ris-Rez Hits Phase III Survival Endpoint in Small-Cell Lung Cancer
Hansoh Pharma has announced positive Phase III results for risvutatug rezetecan, also known as Ris-Rez, an investigational lung cancer treatment licensed by GSK outside Greater China. The ARTEMIS-008 trial was conducted in China and focused on patients with advanced or relapsed small-cell lung cancer... (read more)
Why Endometriosis Needs New Treatment Approaches with EndoCyclic Therapeutics’ Dr. Tanya Petrossian
In this week’s episode of the Xtalks Life Science Podcast, host Vera Kovacevic, Editor-in-Chief at Xtalks, spoke with Dr. Tanya Petrossian, CEO and Founder of EndoCyclic Therapeutics, a biopharmaceutical company developing a non-hormonal therapeutic approach for endometriosis... (read more)
This Month's Question
New Approach Methodologies (NAMs), including cell-based models, organoids, organ-on-chip systems and computer modeling, are playing a larger role in efforts to reduce animal testing in drug development. As the conversation moves from policy to implementation, developers still face questions around validation, technical capabilities, regulatory expectations and confidence in how well these methods predict human responses.
What do you believe is the biggest barrier to wider adoption of NAMs in drug development? Cast your vote here and join the conversation!
Last Month's Results
The results of last month’s poll are now available — check out which skill your peers believe is the most important for life sciences professionals over the next 5 years.
Below are some exciting job opportunities from our member organizations. Click here to explore all the open positions on our website today.